Ignite Creation Date:
2025-12-25 @ 12:35 AM
Ignite Modification Date:
2026-01-06 @ 6:00 AM
Study NCT ID:
NCT04737967
Status:
UNKNOWN
Last Update Posted:
2021-02-04
First Post:
2021-01-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
Sponsor:
Mendel AI
Organization:
Study Overview
Official Title:
The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy
Status:
UNKNOWN
Status Verified Date:
2021-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a double blinded two-arm randomized case-only interventional trial. A total of 60 patients who are to receive Paclitaxel to be included and allocated in two groups. The protocol is to be reviewed by the Research Ethics Committee of Faculty of Medicine Cairo University.
All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine.
The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets (Zimmerman et al., 2016).
The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)
All procedure will be done in Kasr El-Einy Center of Radiation Oncology and Nuclear Medicine.
The first arm (Venlafaxine group) will receive Venlafaxine extended release (37.5 mg) tablets (Zimmerman et al., 2016).
The second arm (Memantine group) will receive memantine 10 mg once daily (Morel et al., 2016)
Detailed Description:
None
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: